Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för BGT226. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

7 träffar

Bibliografisk träff 2013-01-08

PAK1 mediates resistance to PI3K inhibition in lymphomas.

Walsh K, McKinney MS, Love C, Liu Q, Fan A, Patel A, Smith J, Beaven A, Jima DD, Dave SS.

Clin Cancer Res · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-12-1060

Bibliografisk träff 2012-03-27

NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity.

Fokas E, Yoshimura M, Prevo R, Higgins G, Hackl W, Maira SM, Bernhard EJ, McKenna WG, Muschel RJ.

Radiat Oncol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/1748-717x-7-48

Bibliografisk träff 2012-02-22

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.

Markman B, Tabernero J, Krop I, Shapiro GI, Siu L, Chen LC, Mita M, Melendez Cuero M, Stutvoet S, Birle D, Anak Ö, Hackl W, Baselga J.

Ann Oncol · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1093/annonc/mds011

Bibliografisk träff 2012-01-01

Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma.

Baumann P, Schneider L, Mandl-Weber S, Oduncu F, Schmidmaier R.

Anticancer Drugs · journal article · DOI 10.1097/cad.0b013e32834c8683

Bibliografisk träff 2011-12-15

The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines.

Glienke W, Maute L, Wicht J, Bergmann L.

Tumour Biol · research support, non-u.s. gov't; journal article · DOI 10.1007/s13277-011-0290-2

Bibliografisk träff 2011-10-05

Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.

Chang KY, Tsai SY, Wu CM, Yen CJ, Chuang BF, Chang JY.

Clin Cancer Res · research support, non-u.s. gov't; journal article · DOI 10.1158/1078-0432.ccr-11-0796

Bibliografisk träff 2011-03-01

Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.

Sanchez CG, Ma CX, Crowder RJ, Guintoli T, Phommaly C, Gao F, Lin L, Ellis MJ.

Breast Cancer Res · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1186/bcr2833